After a year that has seen landmark US approvals and launches for generic versions of albuterol as well as a sudden withdrawal from the market by one key player, Sandoz has further shaken things up by striking a deal to in-license commercial distribution rights to both the Proventil HFA (albuterol sulfate) brand and an authorized generic version from Kindeva Drug Delivery, with “immediate generic availability” for the bronchospasm treatment.
“The immediate launch of our authorized generic will help ensure a reliable supply of albuterol medicines” and ensure that “patients have access to an important medicine at an affordable price,” Sandoz announced, highlighting the increased demand seen for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?